In a trio of studies, investigators were able to demonstrate equivalency of Samsung Bioepis’ trastuzumab biosimilar in various settings.
Incheon, Republic of Korea company Samsung Bioepis reported clinical trial data from 3 studies of its trastuzumab biosimilar (Ontruzant) that demonstrate equivalency to the reference product, Herceptin, in various settings. In April, the biosimilar was launched on the US market.
The results will be presented at the upcoming American Society of Clinical Oncology meeting (ASCO20 Virtual Scientific Program).
Ontruzant Combination Therapy pCR Rate
Using data from the Danish Breast Cancer Cooperative Group registry, investigators sought to assess the real-world efficacy of combining neoadjuvant chemotherapy (NACT) with Ontruzant and pertuzumab in patients with HER2-positive early breast cancer.
Overall, 56% of patients (n = 215) achieved a pathologic complete response (pCR) and 68% of patients who were node positive before receiving the combination of NACT, Ontruzant, and pertuzumab had tumor-free axillary nodes after completing the regimen.
Investigators said the pCR rate for the Ontruzant combination that was comparable to that seen in clinical studies involving Herceptin in combination with NACT and pertuzumab.
Cardiotoxicity of Ontruzant Plus Pertuzumab
Because cardiotoxicity is a concern during trastuzumab therapy, it is important to understand the safety profile of biosimilars in this regard. Investigators at the Medical University of Graz in Austria sought to measure potential decline in left ventricular ejection fraction (LVEF) for patients with HER2-positive breast cancer receiving Ontruzant and pertuzumab.
All patients (n = 35) had a normal baseline LVEF (> 50%) prior to starting Ontruzant and pertuzumab, and the median LVEF was 60%. At the end of treatment (median 4 cycles), the median LVEF was 60%.
The safety and efficacy profile of Ontruzant and pertuzumab was consistent with Herceptin and pertuzumab, researchers said.
Cardiac Safety and Survival by ADCC Status
In a study of long-term cardiac safety and survival, investigators evaluated Ontruzant versus Herceptin in patients stratified by antibody-dependent cell-mediated cytotoxicity (ADCC) status.
They enrolled 367 patients, with 186 receiving Ontruzant and 181 receiving Herceptin. During a median follow-up of 53 months, the incidence of asymptomatic LVEF decrease was low (1 patient on Ontruzant and 2 on Herceptin), with all patients recovering with LVEF ≥50%. There were no cases of symptomatic congestive heart failure, cardiac death, or other significant cardiac conditions reported.
The 4-year event-free survival rates were 83.4% for the biosimilar and 80.7% for the reference product (HR, 0.77). The 4-year overall survival rates were 94.3% versus 89.6% (HR, 0.53), respectively.
“Comparable long-term cardiac safety and survival at 4-years supports biosimilarity,” investigators wrote.
The ASCO20 Virtual Scientific Program will be presented May 29 to 31, 2020.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Achieving PFS in Advanced Gastric Cancer With HLX02 Biosimilar, Chemotherapy
November 23rd 2024In a phase 2 study, the addition of HLX22, an anti-HER2 antibody, to HLX02 biosimilar and XELOX (oxaliplatin and capecitabine) chemotherapy extended progression-free survival (PFS) in untreated HER2-positive advanced gastric cancer patients.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.